ArticleThe oncologist2014
FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma.
Article in The oncologist, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial.JAMA network open · 2023Trial
- Repeat cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal carcinomatosis of appendiceal origin.International journal of clinical oncology · 2018Trial
- GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.Journal of translational medicine · 2016Trial
- Review
- Appendiceal-origin pseudomyxoma peritonei masked by culture-positive neutrocytic ascites: a case report.Oxford medical case reports · 2026Article
- Pseudomyxoma peritonei presenting with pyloric obstruction: a case report.Journal of surgical case reports · 2026Article
- Consensus Guideline for the Management of Patients with Appendiceal Tumors, Part 1: Appendiceal Tumors Without Peritoneal Involvement.Annals of surgical oncology · 2026Article
- Intra-Tumoral Mucolytic Therapy for Unresectable Pseudomyxoma Peritonei: Results of a Single-Center Expanded Access Program.Annals of surgical oncology · 2026Article
- Assessing the Annual Risk of Recurrence Following Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Diffuse Malignant Peritoneal Mesothelioma Patients.Annals of surgical oncology · 2025Article
- Article
- Systemic chemotherapy in patients with unresectable pseudomyxoma peritonei from low-grade appendiceal mucinous neoplasms: a case series.Journal of gastrointestinal oncology · 2025Article
- Neoplastic appendiceal mucinous lesions: a narrative review of the literature from an oncologist's perspective.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Review
- Defining a role for systemic chemotherapy in local and advanced appendix adenocarcinoma.ESMO open · 2023Article
- Treatment outcome analysis of bevacizumab combined with cyclophosphamide and oxaliplatin in advanced pseudomyxoma peritonei.World journal of gastrointestinal surgery · 2023Article
- Article
- Rare Mucinous Adenocarcinoma of the Appendix Undergoing Multiple Recurrent Surgical Interventions.Cureus · 2023Article
- Article
- The role of chemotherapy in the treatment of advanced appendiceal cancers: summary of the literature and future directions.Therapeutic advances in medical oncology · 2022Review
- Molecular profiling of appendiceal serrated lesions, polyps and mucinous neoplasms: a single-centre experience.Journal of cancer research and clinical oncology · 2021Article
Corrections and comments
- Commented on by
- Commented on byIn reply.2015
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe standard treatment of peritoneal pseudomyxoma is based on cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC). The establishment of newer systemic treatments is an unmet clinical need for unresectable or relapsed peritoneal pseudomyxoma. The aim of our study was to assess the activity of chemotherapy with 5-fluorouracil and oxaliplatin (FOLFOX-4 regimen) in terms of response rate in this subset of patients. MATERIALS AND
methodsPatients were included in a single-center, observational study and treated with FOLFOX-4 administered every 2 weeks for up to 12 cycles or until progressive disease or unacceptable toxicity.
resultsTwenty consecutive patients were reviewed from July 2011 to September 2013. Only partial responses were observed, with an objective response rate of 20%. Median progression-free survival and overall survival were 8 months and 26 months, respectively. Two patients were able to undergo laparotomy with complete cytoreduction and HIPEC in one case. Safety data for FOLFOX-4 were consistent with the literature. By means of a mutant enriched polymerase chain reaction, KRAS mutation was found in 16 of 19 cases (84%), and MGMT promoter methylation was found in 8 (42%, all KRAS mutant).
conclusionFOLFOX-4 chemotherapy is tolerable and active in patients with peritoneal pseudomyxoma when disease is deemed unresectable or relapsed after peritonectomy and HIPEC. The identification of predictive biomarkers, such as KRAS for resistance to anti-epidermal growth factor receptor monoclonal antibodies and MGMT for response to temozolomide, is a priority for the development of evidence-based treatment strategies for peritoneal pseudomyxoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.